<DOC>
	<DOCNO>NCT00855972</DOCNO>
	<brief_summary>The purpose research obtain data information safety effectiveness low dose naltrexone ( LDN ) treat symptom juvenile primary fibromyalgia syndrome . This dose finding study find whether LDN help symptom juvenile fibromyalgia , dose .</brief_summary>
	<brief_title>Low Dose Naltrexone Treatment Juvenile Primary Fibromyalgia Syndrome</brief_title>
	<detailed_description>In pilot dosage-finding efficacy study , experimentally test whether LDN reduces symptoms JPFS . We recruit 40 child JPFS . Participants screen via JPFS criterion Yunus Masi . The study open-label test various dos LDN determine whether LDN reduces JPFS symptom , appropriate dose . Primary endpoint daily pain , fatigue , sleep . The protocol design take 18 week . There total 10 study visit , take place approximately every 2 week .</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Generalized musculoskeletal ache 3 month duration 2 . Moderatesevere pain 5 11 tender point 3 . Age 7 17 4 . Male female 1 . Diagnosed rheumatic autoimmune condition contribute pain 2 . Abnormal laboratory result ( Rf , ANA , ESR ) 3 . Use opioid analgesic last 6 month 4 . Severe depression and/or anxiety evidence diagnosis either disorder , evidence base clinical interview patient parent time screen . 5 . Current previous psychiatric disorder require hospitalization 6 . Inability operate Palm OSÂ® handheld device selfreports 7 . Inability understand English 8 . Inability attend session Stanford lab every 3 week 9 . Pregnancy plan pregnancy , breastfeed 10 . Abnormal liver functioning test</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>